Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

(146)

Special and

acquisition

related charges 84 - (84) - -

Equity income (2,049) - - - (2,049)

(Loss)/income

before income taxes (1,215) 4,080 (453) 197 2,609

Income tax expense 258 89 2 1 350

Net (loss)/income

before cumulative

effect of a change

in accounting

principle $(1,473) $3,991 $(455) $196 $2,259

Cumulative effect

of a change in

accounting principle,

net of tax - - - - -

Net (loss)/income $(1,473) $3,991 $(455) $196 $2,259

Preferred stock

dividends 118 - - - 118

Net (loss)/income

available to

common

shareholders $(1,591) $3,991 $(455) $196 $2,141

Diluted (loss)/

earnings per

common share:

(Loss)/earnings

available to

common shareholders

before cumulative

effect of a change

in accounting

principle $ (1.04) $1.37

Cumulative effect

of a change in

accounting principle,

net of tax - -

Diluted (loss)/

earnings per

common share $ (1.04) $1.37

Average common

shares outstanding

-diluted 1,536 1,607

SCHERING-PLOUGH CORPORATION

Reconciliation from Reported Net Income Available to Common Shareholders and Reported Diluted Earnings Per Common Share to As Reconciled Amounts for Net Income

Available to Common Shareholders and Diluted Earnings per Commo
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014   Sequenom, Inc. (NASDAQ: ... provides innovative genetic analysis solutions, and Mayo Medical ... services in the United States , ... patents and applications. "We have great appreciation ... care, and we welcome the opportunity to partner with ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... team of researchers has created a new way ... textures. These surfaces, made by self-assembly of carbon ... including controllable mechanical stiffness and strength, or ... direction. , "We have demonstrated that mechanical forces ... complex three-dimensional microstructures, and that we can independently ...
(Date:7/29/2014)... 29, 2014  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: IPXL).  Such investors are advised to ... or 888-476-6529, ext. 237. The investigation ... directors have violated Sections 10(b) and 20(a) of the ... July 29, 2014, Impax Laboratories, Inc. (the "Company") issued ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... Mass., Dec. 15 Repligen Corporation (Nasdaq: RGEN ) ... funding to support the ongoing development of new treatments for ... grant will support the completion of preclinical GLP toxicology testing ... trials. Support from the MDA not only provides important ...
... , , , , , , , ... Board : AEMD) announced today that Dr. Jeff Schorey and Dr. ... Exosome Sciences, Inc. (ESI). Both Dr. Schorey and Dr. Comper are ... of Aethlon Medical, was recently formed to leverage the discovery that ...
... , , PLYMOUTH, Minn., Dec. 15 The Mosaic ... quarter fiscal year 2010 earnings results and financial tables on Tuesday, ... York Stock Exchange. Results will be available on Mosaic,s website ... call with presentation slides on Wednesday, January 6, 2010, to discuss ...
Cached Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2
(Date:7/28/2014)... have pinpointed a mechanism in part of the brain that ... it to both type 1 and type 2 diabetes. The ... Proceedings of the National Academies of Sciences . , ... a part of the hypothalamus known as the ventromedial nucleus ... glucose levels in the blood," said lead author Sabrina Diano, ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... St. Jude Children,s Research Hospital study found that 73 ... doubled their risk of developing metabolic syndrome and related ... The results appear in the current issue of the ... the 1,598 adult survivors of childhood cancer in the ... risk factors like high blood pressure, abdominal obesity, elevated ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... Hunting for meat in the African rainforests has halved the ... consequences. The decline in the number of primates causes a ... this leads to a reduction in the numbers of important ... shown in new research from Lund University in Sweden. ...
... 2013 - Elsevier, a world-leading provider of scientific, technical ... announce the launch of Wound Medicine The ... and Applications . Published in print and ... is devoted to the clinical, scientific and health economics ...
... to determine mercury exposure from dental amalgam fillings may ... from fillings, according to University of Michigan researchers. ... vapor into the mouth. But both the amount of ... presents a significant health risk remain controversial. Public ...
Cached Biology News:Hunting for meat impacts on rainforest 2Elsevier announces the launch of a new journal: Wound Medicine 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 2Measuring mercury: Common test may overestimate exposure from dental amalgam fillings 3
... supplied as 10X concentrated solutions. REact Buffer SetConsists ... the REact buffers and one 250 microl vial ... 1 ml vials of REact 1 Buffer four ... 1 ml vials of REact 3 Buffer and ...
Request Info...
Services include subcloning into an expression vector. Tagged protein will be expressed in small scale for testing yield and solubility and then in 1L culture for large scale affinity purification. E...
...
Biology Products: